JP2022501423A5 - - Google Patents

Info

Publication number
JP2022501423A5
JP2022501423A5 JP2021538933A JP2021538933A JP2022501423A5 JP 2022501423 A5 JP2022501423 A5 JP 2022501423A5 JP 2021538933 A JP2021538933 A JP 2021538933A JP 2021538933 A JP2021538933 A JP 2021538933A JP 2022501423 A5 JP2022501423 A5 JP 2022501423A5
Authority
JP
Japan
Prior art keywords
pharmaceutical
vesicle
cholesterol
formulation
pharmaceutical agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021538933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501423A (ja
JP7487892B2 (ja
Filing date
Publication date
Priority claimed from GBGB1814959.1A external-priority patent/GB201814959D0/en
Application filed filed Critical
Publication of JP2022501423A publication Critical patent/JP2022501423A/ja
Publication of JP2022501423A5 publication Critical patent/JP2022501423A5/ja
Application granted granted Critical
Publication of JP7487892B2 publication Critical patent/JP7487892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021538933A 2018-09-14 2019-09-13 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用 Active JP7487892B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1814959.1 2018-09-14
GBGB1814959.1A GB201814959D0 (en) 2018-09-14 2018-09-14 Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
PCT/GB2019/000134 WO2020053541A1 (en) 2018-09-14 2019-09-13 Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses

Publications (3)

Publication Number Publication Date
JP2022501423A JP2022501423A (ja) 2022-01-06
JP2022501423A5 true JP2022501423A5 (cg-RX-API-DMAC7.html) 2022-09-21
JP7487892B2 JP7487892B2 (ja) 2024-05-21

Family

ID=64013381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538933A Active JP7487892B2 (ja) 2018-09-14 2019-09-13 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用

Country Status (8)

Country Link
US (1) US11524080B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849511B1 (cg-RX-API-DMAC7.html)
JP (1) JP7487892B2 (cg-RX-API-DMAC7.html)
AU (1) AU2019337456B9 (cg-RX-API-DMAC7.html)
CA (1) CA3113047A1 (cg-RX-API-DMAC7.html)
DK (1) DK3849511T3 (cg-RX-API-DMAC7.html)
GB (2) GB201814959D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020053541A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566019B2 (en) * 2020-04-02 2023-01-31 Southern Research Institute 2-pyrimidone analogs as potent antiviral agents against alphaviruses
CN116350588B (zh) * 2023-01-13 2024-09-24 华中科技大学 一种载抗生素微生物囊泡及其制备方法和应用
GB202303291D0 (en) * 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323561A (en) * 1977-09-06 1982-04-06 Temple University Of The Commonwealth System Of Higher Education Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants
JPH04159216A (ja) * 1990-10-22 1992-06-02 Japan Tobacco Inc グルコサミン誘導体を膜材として含有するリポソーム
GB9515868D0 (en) 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
WO2009129616A1 (en) * 2008-04-21 2009-10-29 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US9907746B2 (en) * 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es) * 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
CA2840079C (en) * 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2013059617A1 (en) * 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
WO2013072768A2 (en) * 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) * 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) * 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9539273B2 (en) * 2012-08-04 2017-01-10 Edh Biotech Corp Targeted delivery of anti-fungal agents
MX2016005232A (es) * 2013-10-22 2017-01-19 Aradigm Corp Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida.
RU2016143591A (ru) * 2014-04-08 2018-05-08 Арадайм Корпорейшн Липосомы, в которых образуются нанокристаллы лекарственного вещества после замораживания-оттаивания
US20160228573A1 (en) * 2014-08-14 2016-08-11 L.E.A.F. Holdings Group Llc Liposome encapsulated affinity drug

Similar Documents

Publication Publication Date Title
US20170165375A1 (en) Antibiotic protocells and related pharmaceutical formulations and methods of treatment
JP6050822B2 (ja) ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用
BG108274A (bg) Конюга'и о' хидрок'иалкил'корбяла (has) и ак'ив...н ингр...ди...н'
CN106604750A (zh) 治疗骨髓瘤
US20190175747A1 (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer
JP6836510B2 (ja) 少なくとも2つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
AU2015228463A1 (en) Liposomal compositions for mucosal delivery
CN105163743A (zh) 用于治疗幽门螺杆菌的药物组合物
CN110573166A (zh) 用于癌症治疗的吉西他滨衍生物
CA3074985A1 (en) Compounds and methods for treating cancer
JP4513007B2 (ja) 薬物吸収性改善剤
AU779922B2 (en) Formulations for parenteral use of estramustine phosphate and amino acids
CN120826242A (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
JP7487892B2 (ja) 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用
JP2022529996A (ja) 高濃度タンパク質製剤の粘度を低減させるための低分子量ポリビニルピロリドン(pvp)の使用
EP3386540A1 (en) Novel adjuvant formulations
JPH0136445B2 (cg-RX-API-DMAC7.html)
CN110787301A (zh) CTLA-4 Aptamer靶向共负载PD-1 siRNA纳米颗粒及其制备和应用
JP7149991B2 (ja) 発泡剤を含む抗微生物組成物
CN105263499B (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
CN115721732A (zh) 抗体偶联药物的药物组合物、制剂及其制备方法、用途
CN1177583C (zh) 具有改进药理学性质的非肠胃道使用的雌莫司汀磷酸盐制剂
CN1374857A (zh) 肠胃外用磷雌氮芥和磺烷基醚环化糊精制剂
CN1511037A (zh) 非肠道使用的雌莫司汀磷酸盐和白蛋白的制剂
CA3157379A1 (en) Delivery system complexes comprising a precipitate of an active agent and methods of use